Pharmexec.com published our article: “Breaking Orbit: How pharmaceutical leaders at established companies can still disrupt the status quo and change the game.“
Why do some successful pharmaceutical organizations become “The Disruptors” and others become “The Disrupted?” What type of leadership does it take to break through the constraints of success to reimagine what’s possible, and innovate to keep bringing new products and services to life to keep pace with a world that is changing in so many ways faster than ever before?
In the face of the COVID-19 health emergency, multiple pharmaceutical companies have heroically re-prioritized their business models to rapidly develop, seek approvals for, and launch sorely needed COVID-19 vaccines and therapeutics. But in the absence of a similarly compelling emergency, how will pharmaceutical leaders break out of the orbit of their status quo? How can they help their company innovate and transform to meet emerging challenges arising from constantly shifting therapeutic needs along with evolving environmental, social, and governance issues?